0102030405
USP1 (Ubiquitin-Specific Peptidase 1) inhibitor
2024-07-19
- Program：USP1 (Ubiquitin-Specific Peptidase 1) Inhibitor
- Indication: Cancers with BRCA mutations or HRD (homologous recombination deficiency), including ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, etc
- Status：PCC
- Collaboration Opportunity: Equity financing, cooperative development, product transfer, etc.
- Highlights：
- USP1 is a novel synthetic lethal target. In patients who do not respond to or are resistant to PARP inhibitors, USP1 inhibitors can also be effective. Combining USP1 inhibitors with PARP inhibitors can enhance treatment efficacy and prevent or delay the development of resistance.
- Demonstrates significant in vitro and in vivo activity. Good safety profile, with no observed safety issues.